Waldencast Acquisition Corp. a skin care company, provides advanced skin care treatments. Its products are designed to help minimize the appearance of premature skin aging, skin damage, hyperpigmentation, acne, and sun damage primarily available through dermatologists, plastic surgeons, medical spas, and other skin care professionals. Its portfolio includes Obagi Medical that provides transformational skin care products formulated to minimize signs of skin aging, address dark spots, hyperpigmentation, fine lines, and wrinkles and to protect and enhance skin tone and texture; and Obagi Clinical that offers skin care products designed to prevent the early signs of skin aging. The company was founded in 1988 and is based in White Plains, New York.

Waldencast plc

Waldencast is a self-described global beauty and wellness multi-brand platform.

Waldencast

Waldencast is a holding company and investment fund that incubates and accelerates early stage beauty and wellness brands and helps them rapidly create scale and profitability via industry specific operational expertise. Waldencast invests in brand-led business models and goes beyond traditional incubation and acceleration to develop a collective of innovative and unique brands that place responsible entrepreneurship at the heart of its operations.  Waldencast has offices in New York and London and has an investment portfolio in North America, Europe, and Latin America.

The selection of brands to participate in the community is as much driven by the strength of the brand concept and business model as it is by our shared human and social values: sustainability, responsibility, inclusivity.  We believe brands that marry purpose, art, beauty, and design with industry and commerce to make the planet and the lives of those in it better.

Individuals that are part of the Waldencast collective are as much driven by the strength of the brands’ ideas, as it is by sharing our dreamer/maker values: ambition with humility, idealism with practicality, grit with empathy, vision with action.

We have the spirit of a challenger, a disruptor, a game-changer. We are a start-up and we intend to stay in the attitude of a start-up regardless of our success.

Costa Brazil

2024 AWARD WINNING BROW SERUM🎉

InStyle has recognized Obagi Nu-Cil™ Eyebrow Boosting Serum as the Best Brow Serum in their Best Beauty Buys 2024 product roundup! 

“I was introduced to this powerhouse brow serum by board-certified dermatologist Mona Gohara, M.D.  …So it's safe to say I'm hooked.” writes Kara Jillian Brown

Thank you to our Obagi Fam and healthcare providers for the continuous love you show our products.

Visit your Obagi provider to learn more about this great product! 
#obagi #obagimedical #obagiskincare

Read the full article here:
https://lnkd.in/giiJuG-M

We're #hiring a new Amazon Brand Manager in Greater London, England. Apply today or share this post with your network.

Congratulations to our portfolio company C16 Biosciences for this recognition!

We are excited to participate in TD Cowen’s 8th annual conference 2024 with Oliver Chen, CFA and Jonna Kim, CFA.

We’re #hiring a new Glaze North America Key Account Director in United States. Apply today or share this post with your network.

	Dec '20	Dec '21	Dec '22	Dec '23
average inventory			38.00M -	55.03M 44.84%
average payables		136.48K -	18.28M 13,291.68%	25.98M 42.15%
average receivables			19.14M -	20.99M 9.65%
book value per share		8.12 -		6.85 -
capex per share				-0.02 -
capex to depreciation				-0.03 -
capex to operating cash flow				0.07 -
capex to revenue				-0.01 -
cash per share		0.04 -		0.25 -
days of inventory on hand				148.29 -
days payables outstanding		10.91 -		74.80 -
days sales outstanding				37.53 -
debt to assets		0.00 -	0.18 4,125.86%	0.16 14.90%
debt to equity		0.01 -	0.31 5,930.05%	0.26 16.69%
dividend yield
earnings yield		-0.04 -		-0.09 -
enterprise value		355.48M -	190.55M 46.40%	1.15B 504.77%
enterprise value over ebitda		-93.91 -		-53.77 -
ev to operating cash flow		-435.81 -		-38.70 -
ev to sales				5.28 -
free cash flow per share		-0.02 -		-0.35 -
free cash flow yield		-0.00 -		-0.03 -
graham net net		-1.54 -		-2.26 -
graham number		8.57 -		12.34 -
income quality		0.06 -		0.33 -
intangibles to total assets	0 -	0	0.89 Infinity%	0.32 64.08%
interest coverage				-4.33 -
interest debt per share		0.04 -		1.99 -
inventory turnover				2.46 -
invested capital		0.01 -	0.31 5,930.05%	0.26 16.69%
market cap		355.49M -		997.27M -
net current asset value	-177.74K -	-54.89M 30,783.99%	-199.13M 262.76%	-166.11M 16.58%
net debt to ebitda		0.00 -		-7.24 -
net income per share		-0.40 -		-0.99 -
operating cash flow per share		-0.02 -		-0.33 -
payables turnover		33.46 -		4.88 -
receivables turnover				9.72 -
research and ddevelopement to revenue				0.01 -
return on tangible assets		-0.04 -		-0.13 -
revenue per share				2.39 -
roe		-0.05 -		-0.14 -
roic		-0.03 -		-0.10 -
sales general and administrative to revenue
shareholders equity per share		8.12 -		6.85 -
stock based compensation to revenue
tangible asset value	-10.95K -	290.19M 2,650,003.81%	-173.89M 159.92%	434.65M 349.96%
tangible book value per share		8.12 -		4.77 -
working capital	-177.74K -	1.34M 854.26%	18.54M 1,282.78%	44.61M 140.66%

NASDAQ:WALD

Waldencast

Last Close

3.47

26/07 20:00

Market Cap

456.93M

Beta: -

Volume Today

73.17K

Avg: 5.58K

PE Ratio

−2.75

PFCF: 366.52

Preview